Processa Pharma Files 8-K, Confirms Nasdaq Listing & Corporate Details

TL;DR

**Processa Pharma filed an 8-K, confirming its Nasdaq listing and corporate info.**

AI Summary

Processa Pharmaceuticals, Inc. filed an 8-K on February 6, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. The filing confirms the company's current status and details, including its incorporation in Delaware, its business address at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076, and its common stock (PCSA) listed on the Nasdaq Capital Market. This matters to investors as it provides updated, official company information, ensuring transparency and confirming its listing status, which is crucial for trading and regulatory compliance.

Why It Matters

This filing provides current, official information about Processa Pharmaceuticals, Inc., confirming its operational details and continued listing on the Nasdaq Capital Market, which is essential for investor confidence and market transparency.

Risk Assessment

Risk Level: low — This 8-K is a routine informational filing and does not indicate any immediate financial or operational risks.

Analyst Insight

A smart investor would note this routine filing confirms Processa Pharmaceuticals, Inc.'s current corporate details and Nasdaq listing, but it doesn't contain new material information to prompt immediate action. It serves as a confirmation of ongoing compliance.

Key Numbers

• February 6, 2024 — Date of Report (The date of the earliest event reported in this 8-K filing.)
• 001-39531 — Commission File Number (The SEC file number for Processa Pharmaceuticals, Inc.)
• $.0001 — Par Value (The par value per share of Processa Pharmaceuticals, Inc.'s common stock.)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Processa Pharmaceuticals, Inc.
• Nasdaq Capital Market (company) — exchange where Processa Pharmaceuticals, Inc.'s common stock is registered
• PCSA (company) — trading symbol for Processa Pharmaceuticals, Inc.'s common stock
• 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 (company) — principal executive offices address
• February 6, 2024 (date) — date of earliest event reported and filing date
• 001-39531 (dollar_amount) — Commission file number
• 45-1539785 (dollar_amount) — I.R.S. Employer Identification Number
• $.0001 (dollar_amount) — par value of common stock

FAQ

Key Financial Figures

• $1.00 m — ompany has regained compliance with the $1.00 minimum closing bid price requirement for

Filing Documents

• form8-k.htm (8-K) — 38KB
• ex99-1.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 7KB
• 0001493152-24-005029.txt ( ) — 232KB
• pcsa-20240206.xsd (EX-101.SCH) — 3KB
• pcsa-20240206_lab.xml (EX-101.LAB) — 33KB
• pcsa-20240206_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 7380 Coca Cola Drive , Suite 106 , Hanover , Maryland 21076 (Address of Principal Executive Offices, Including Zip Code) (443) 776-3133 (Registrant's Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock: Par value $.0001 PCSA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On February 6, 2024, Processa Pharmaceuticals, Inc. (the "Company") announced they received written notification from the NASDAQ Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2) (the "Minimum Bid Price") and that the matter is now closed. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Press release announcing the Company regained compliance with the Nasdaq Minimum bid price rule. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on February 6, 2024. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR